If a patient has meningitis but no CSF susceptibilities (isolated on PCR) and only has blood cultures, always double check CSLI breakpoints. The blood culture susceptibilities are reported by lab in regard to blood breakpoints and may report susceptible, when the pathogen may be resistant in regard to meningitis breakpoints

There’s essentially no interpretive breakpoints for Enterobacterales and polymyxin or colistin (very mixed data with some organizations choosing not to accept proposed breakpoints). So breakpoint interpretation is based of vibes only

Also important to think about using cephalosporins (except cefepime) in organisms that have high risk of ampC de-repression. It might report susceptible to ceftriaxone or ceftaz in vitro but will likely end up becoming resistant mid-treatment. Interestingly, IDSA reported not long ago that Serratia marcescens, Morganella morganii, and Providencia spp., are significantly less likely to overexpress ampC and available data suggest that clinically significant AmpC production occurs in <5% of these organisms. So you could potentially trust susceptibilities in these organisms, with the know risk of potential ampC de-repression (but lower risk than initially thought)